Global Oligonucleotide Synthesis Market - 2020-2027
|寡核苷酸合成的全球市場:2020年∼2027年 Global Oligonucleotide Synthesis Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global oligonucleotide synthesis Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Oligonucleotide synthesis is the chemical synthesis of relatively short fragments of nucleic acids with defined chemical structure. The technique is extremely useful in current laboratory practice because it provides a rapid and inexpensive access to custom-made oligonucleotides of the desired sequence. The market is growing due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
The global oligonucleotide synthesis market growth is driven by its extensive used for the selection and determination of DNA sequences (hybridization probes or affinity purification), gene construction, and site-directed mutagenesis .
Increasing research activities in the pharmaceutical and biotechnology sectors
The increasing prevalence of chronic and life-threatening diseases has prompted pharmaceutical companies and research firms to focus on R&D activities for the development of effective therapeutics. As a result, advances in life sciences research is leading to an improved understanding of biological systems. The development of oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will lead to the expansion of the global oligonucleotide synthesis market.
Increasing focus on new oligonucleotide therapies will drive the market growth
Pharmaceutical and biotechnological companies are focusing on R&D of new oligonucleotide drugs due to the presence of the limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes that are inaccessible by small-molecule drugs and biologic drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Currently, many oligonucleotide therapeutics are in various stages of clinical trials for the treatment of many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and increase in R&D is expected to have a positive impact on the overall market growth.
Regulatory issues associated with oligonucleotide therapeutics is likely to hinder the market growth
However, regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery may hamper the growth of the oligonucleotide synthesis market over the forecast period.
Over the years, growth of oligonucleotides has been widespread in the healthcare industry. They are generally used to determine DNA sequences in gene reconstruction and site-directed mutagenesis. They are also used to inhibit gene expression in in-vitro studies for diagnostic purposes. Such a vast applicability of oligonucleotides have prompted an array of developments in synthetic chemistry.
Integrated DNA Technologies, for instance, is a company extensively engaged in the development of oligonucleotides up to 200 base length, suitable for usage in manufacturing mini-genes.
COVID-19 Impact Analysis
The global oligonucleotide synthesis market has received immense impetus from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19. Pioneering research and development is being undertaken by bioSynthesis, a leading vendor. It has doled out ready-to-use cocktail mixes such as the SARS-CoV-2 N1 Oligo Mix, the SARS-CoV-2 N2 Oligo Mix and the Human RNase P (RP) Oligo Mix respectively. Such breakthroughs are generating a level of optimism amongst healthcare providers and stimulating them to keep the anti-coronavirus battle raging., hence, expected to boost the market growth over the forecast period.
Market Segment Analysis
By product, the oligonucleotide synthesis market is classified into reagents, equipment, synthesized oligonucleotides (oligonucleotide-based drugs, primers, probes, large-scale synthesized oligonucleotides, and others)
Synthesized oligonucleotides segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Synthetic oligonucleotides in therapeutics for treating neurodegenerative diseases and cancer is anticipated to heighten market prospects. Synthetic oligonucleotides are most reliably produced using a solid synthesis approach. It allows oligonucleotides to be custom designed to produce specific genetic sequences. To obtain the desired oligonucleotide each building block, comprising on a nucleic acid is coupled sequentially to the growing chain until the desired product is achieved. Once complete the oligonucleotide chain is released from the solid support used for synthesis, deprotected and the final product purified.
It is also common to see synthetic oligonucleotides modified at the ribose sugar to form bridged nucleic acids or linked nucleic acids which is promising for antisense and silencing RNA applications, the process by which gene expression is negatively affected leading to sequence specific gene silencing. These bridged nucleic acids lead to the formation of constrained or inaccessible oligonucleotides which introduces additional stability to the molecule. The conformational inflexibility bridging the sugar moiety brings results in a gain in binding affinity of the oligonucleotide to complementary strands of RNA and DNA.
Oligonucleotide-based drugs: Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience. More than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical / clinical phases of development. In fact, more than 270 registered clinical trials focused on oligonucleotides, till 2019, it is worth noting that the maximum (34) number of trials were registered in 2019.
Probes : Probe is a small fragment of DNA or RNA used to detect the target DNA or RNA in the sample by molecular hybridization. They are also known as molecular markers. The length of the probe can vary (100 to 1000 bases), and probe nucleotides are complementary to the part of the target sequence. For the ease of detection, probes are labeled with radioactive isotopes or with fluorescent dyes or antibodies. Probes bind with the complementary bases of the target sequence and reveal the presence of the target DNA or RNA in the sample. There are two main methods of labelling probes: end labeling and nick translation. Probes are categorized into different types including DNA probes, RNA probes, cDNa probes and synthetic oligonucleotides probes, and they are prepared using different techniques.
Primers : Primer is a small stretch of DNA or RNA that serves as a starting point for DNA replication. This acts as a starting point for DNA synthesis. Primer anneals with the complementary bases of the DNA strands. They are generally not labeled. The target sequence is flanked by two primers known as forward primer and reverse primer. Specificity and complementarity are the primary factors in the designing of primers. Secondary structures should also be avoided.
Hospitals are expected to dominate the global oligonucleotide synthesis market during the forecast period
The significant number of inpatient and outpatient visits in hospitals coupled with the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease, is driving the market growth in the segment.
However, in the developing countries of Asia-pacific and Africa, the hospital infrastructure is still underdeveloped which is hampering the market in the forecast period. For instance, in India the number of hospital beds per 1,000 population is less than 1, which is well below the World Health Organization (WHO) average of around 2.7 and the Organization for Economic Co-operation and Development (OECD) average of over 5. While some of the recent investments in the hospital sector are as follows, the value of merger and acquisition (M&A) deals across hospitals jumped by a record. This factor will drive the growth of the market in the forecast period.
Market Geographical Analysis
North America region holds the largest market share global oligonucleotide synthesis market
North America region is dominating the global oligonucleotide synthesis market accounted for the largest market share in 2019, due to the increasing R&D activities and the growing number of oligonucleotide-based drugs/therapies being approved by the FDA. The presence of innovators and key players in the U.S. has resulted in higher penetration of products in the market. This has allowed North America to account for a significant revenue share in 2017. Furthermore, the strong foothold of North America in genomics, proteomics, oncology, diagnostic screening, and drug discovery has significantly contributed to maintaining its large share.
Government and private entities are investing in the development of academic and research infrastructure in North America. This factor is expected to positively boost the market.. Moreover, collaboration among major players and universities for the development of novel approaches to curing chronic conditions through genetic medicine is expected to contribute to the growth of this segment.
Asia-Pacific has the positive market growth due to the fastest adopters of sequencing, array technology, and PCR products due to rapid progress in genomics studies and the healthcare sector. Japan and China are considered the most attractive markets concerning expansion and growth opportunities present in these countries. Also, changing economic scenario, along with high investments in healthcare, life science-related research programs, and genetics, has encouraged global players to enter the Asia Pacific market, thus aiding its growth.
Market Competitive Landscape
The oligonucleotide synthesis market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oligonucleotide synthesis market globally.
Thermo Fisher Scientific Inc.
Overview: Founded in 2006 and is headquartered at Waltham, Massachusetts, the U.S.; Thermo Fisher Scientific Inc. is engaged in providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery, and diagnostics services under the brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services worldwide. The company operates through four business segments, namely, Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Services. The company provides oligonucleotide products through Invitrogen, under life Sciences solutions business segment.
With its subsidiaries and strong network of distribution, the company has its presence across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Product Portfolio: The Company's portfolio comprised its lead Iodine-Water-Pyridine-Tetrahydrofuran Oxidizer Solution (0.02 M), Trifluoroacetic Acid (TFA) Neat Liquid, in addition to Trichloroacetic Acid Dichloromethane, Deblocking Solution targeting high-performance reagents begin with raw materials that must conform to strict specifications.
Key Development: In February 2019, Thermo Fisher Scientific entered into an agreement with BioNTech (Germany). Under the terms of this agreement, BioNTech's messenger RNA (mRNA) manufacturing platform will be supported by Thermo Fisher through the supply of nucleotides, enzymes, and other critical raw materials.
The global oligonucleotide synthesis market report would provide an access to an approx. 63 market data table, 53 figures and 230 pages.
Target Audience 2022
LIST NOT EXHAUSTIVE